Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Brunner

Showing results (221-230 of 427) with videos related to

Pageof 43
Sort By:
American Heart Journal|March 3, 2015
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunctionParul U Gandhi, Shweta R Motiwala, Arianna M Belcher, et al.
European Journal of Heart Failure|May 14, 2013
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHFSandra Sanders-van Wijk, Stefano Muzzarelli, Michael Neuhaus, et al.
European Journal of Heart Failure|February 6, 2020
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trialRobert Stöhr, Vincent M Brandenburg, Gunnar H Heine, et al.
Cost Effectiveness and Resource Allocation : C/E|November 10, 2018
Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trialSara Michelly Gonçalves Brandão, Paulo Cury Rezende, Hans-Peter Brunner-La Rocca, et al.
Lancet (London, England)|September 13, 2005
Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET)Christoph Kaiser, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
International Journal of Care Coordination|February 24, 2018
Improving kNowledge Transfer to Efficaciously RAise the level of Contemporary Treatment in Heart Failure (INTERACT-in-HF): Study protocol of a mixed methods studyKarolien Baldewijns, Sema Bektas, Josiane Boyne, et al.
Autoimmunity|October 3, 2013
Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertensionSteven J Arends, Jan G M C Damoiseaux, Adriaan M Duijvestijn, et al.
Journal of the American College of Cardiology|May 3, 2005
Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacingAlain Bernheim, Peter Ammann, Christian Sticherling, et al.
American Heart Journal|March 20, 2012
Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapyMicha T Maeder, Hans Rickli, Matthias E Pfisterer, et al.
European Journal of Heart Failure|October 4, 2020
The HFA-PEFF and H<sub>2</sub> FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fractionSandra Sanders-van Wijk, Arantxa Barandiarán Aizpurua, Hans-Peter Brunner-La Rocca, et al.
Pageof 43

Showing results (221-230 of 427) with videos related to

Sort By:
Pageof 43
American Heart Journal|March 3, 2015
Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunctionParul U Gandhi, Shweta R Motiwala, Arianna M Belcher, et al.
European Journal of Heart Failure|May 14, 2013
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHFSandra Sanders-van Wijk, Stefano Muzzarelli, Michael Neuhaus, et al.
European Journal of Heart Failure|February 6, 2020
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trialRobert Stöhr, Vincent M Brandenburg, Gunnar H Heine, et al.
Cost Effectiveness and Resource Allocation : C/E|November 10, 2018
Comparative cost-effectiveness of surgery, angioplasty, or medical therapy in patients with multivessel coronary artery disease: MASS II trialSara Michelly Gonçalves Brandão, Paulo Cury Rezende, Hans-Peter Brunner-La Rocca, et al.
Lancet (London, England)|September 13, 2005
Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET)Christoph Kaiser, Hans Peter Brunner-La Rocca, Peter T Buser, et al.
International Journal of Care Coordination|February 24, 2018
Improving kNowledge Transfer to Efficaciously RAise the level of Contemporary Treatment in Heart Failure (INTERACT-in-HF): Study protocol of a mixed methods studyKarolien Baldewijns, Sema Bektas, Josiane Boyne, et al.
Autoimmunity|October 3, 2013
Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertensionSteven J Arends, Jan G M C Damoiseaux, Adriaan M Duijvestijn, et al.
Journal of the American College of Cardiology|May 3, 2005
Right atrial pacing impairs cardiac function during resynchronization therapy: acute effects of DDD pacing compared to VDD pacingAlain Bernheim, Peter Ammann, Christian Sticherling, et al.
American Heart Journal|March 20, 2012
Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapyMicha T Maeder, Hans Rickli, Matthias E Pfisterer, et al.
European Journal of Heart Failure|October 4, 2020
The HFA-PEFF and H<sub>2</sub> FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fractionSandra Sanders-van Wijk, Arantxa Barandiarán Aizpurua, Hans-Peter Brunner-La Rocca, et al.
Pageof 43